Jielun Zhu

Bio:

Mr. Zhu is a leading KOL on biotech capital formation, business development and the “NewCo” model. He has recently co-founded the first “China-to-China NewCo” Excalipoint Therapeutics, successfully raising US$41 million from top-tier healthcare investors, setting a new record for seed round financing in China. As a renowned industry executive and financier, Mr. Zhu boasts over 20 years of hands-on experience in capital formation for innovative biotech companies. He has led numerous landmark transactions, including the largest ever PIPE deal for Chinese biotechs and multi-billion dollar cross-border licensing transactions. During his tenure as CFO of I-Mab, he led the company’s NASDAQ IPO and oversaw its spectacular post-IPO rise in market cap from US$800 million to US$7 billion within 18 months. At its peak, I-Mab was one of the highest profile Chinese biotech companies, in market cap, liquidity and research coverage. Mr. Zhu was also honored with top rankings from Institutional Investor (II) in the “Best CFO” categories in its All-Asia Executive Team survey. Prior to joining I-Mab, Mr. Zhu led the healthcare sector coverage in Asia for Jefferies, a global powerhouse in healthcare investment banking, and was responsible for cross-border M&A, equity financing and capital market deals worth more than US$10 billion in total. He also took leadership positions in healthcare banking at Deutsche Bank and UBS. Mr. Zhu received his MBA degree from Harvard Business School as a Baker Scholar (high honor) and Bachelor of Arts degree from Wesleyan University as Class Valedictorian.